News About

Medivation’s Xtandi Threatened by J&J’s New Acquisition

Tue, 18 Jun 2013 10:55:52 -0400

One of the biotech laggards of the year, Medivation (NASDAQ: MDVN) saw a very high volume selloff (-6.78% ?$47.41/share) yesterday after rival Johnson & Johnson (NYSE: JNJ) announced the acquisition of Aragon Pharmaceuticals – a company that was developing a Phase II metastatic castration-resistant prostate cancer (mCRPC) drug that the market considers a threat to [...]

(MAA) Bayer’s Xofigo Cleared by the US Food and Drug Administration

Sat, 15 Jun 2013 11:01:31 -0400

Bayer’s (BAYRY) HealthCare segment recently received encouraging news as the US Food and Drug...

Visit StockBlogHub to view complete post.

StockCall Pre-Market Review on ACAD, DNDN, MDVN, CTIC, and SRPT

Thu, 13 Jun 2013 10:55:00 -0400

Dendreon Corp. (DNDN) on Move

Thu, 13 Jun 2013 10:44:47 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8414223 for the full story.

Bio-Wire Equity Surveillance – Closing Bell 6/12/2013

Wed, 12 Jun 2013 16:51:03 -0400

Wednesday, June 12th, 2013 DJIA: -.84% to 14,995.23 S&P 500: -.84% to 1,612.52 NASDAQ: -1.06% to 3,400.43 NYSE Arca – Pharma Index: -.06% to 425.42 Big pharma (Mkt Cap $10 B+) -.89% Mid-sized pharma ($2-10 B) -.90% Small pharma ($300 M to $2 B) -.99% Micro pharma (<$300M) -.23% Notable Jumps by % Gain and Mkt Cap Change Questcor Pharmaceuticals (NASDAQ: QCOR) +7.38% to [...]

Pessimists Continue to Target Dendreon Corporation (DNDN)

Wed, 12 Jun 2013 13:55:00 -0400

Despite the broader market's struggle to recover from yesterday's sell-off, Dendreon Corporation (NASDAQ:DNDN) shares are planted firmly in the black, up about 5.5% at last check...(Read More)

Short Interest Falls in Vertex, Rises in Biogen Idec (VRTX, BIIB)

Wed, 12 Jun 2013 13:29:25 -0400

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates.

The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ:

Options Players Wage on Dendreon

Wed, 12 Jun 2013 03:00:00 -0400

NEW YORK (AVAFIN) -- Dendreon options contracts experienced a new 90-day record for call ...

Sizzling Securities Alert : DNDN, CFN, ARNA, GNBT

Fri, 31 May 2013 17:00:00 -0400

New York, NY -- (SBWIRE) -- 05/31/2013 -- Dendreon Corporation (NASDAQ:DNDN) increased +5.43% to $4.08on number of 4.84M stocks compared to average-daily number of 4.61M stocks after its demonstration at the Deutsche Bank dbAccess Health Care Meeting. After last close, its performance in 2013 appears at -22.87%.

Dendreon (DNDN) to Present Six PROVENGE Abstracts at ASCO

Fri, 31 May 2013 08:15:59 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8381446 for the full story.

Dendreon Announces Presentation of PROVENGE® (sipuleucel-T) Data at the 2013 ASCO Annual Meeting

Fri, 31 May 2013 08:00:00 -0400

Interesting DNDN Put And Call For June 7th

Thu, 30 May 2013 11:10:54 -0400

Investors in Dendreon Corp (DNDN) saw new options begin trading today, for the June 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options chain for the new June 7th contracts and identified one put and one call contract of particular interest.

Interesting DNDN Put And Call For June 7th

Thu, 30 May 2013 11:10:54 -0400

Dendreon (DNDN) Sees Upside Action on Chatter

Thu, 30 May 2013 10:58:34 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8378883 for the full story.

Short Interest in Vertex Rises, in Biogen Idec Falls

Wed, 29 May 2013 13:19:27 -0400

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates.

The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena

Dendreon Corporation (NASDAQ: DNDN) Long Term Investors Alert: Lawsuit Against Directors Filed

Wed, 29 May 2013 08:39:00 -0400

San Diego, CA -- (SBWIRE) -- 05/29/2013 -- A new lawsuit was filed by a current investor in shares of Dendreon Corporation (NASDAQ: DNDN) against certain directors of Dendreon Corporation and current NASDAQ: DNDN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

Commit To Buy Dendreon At $2, Earn 26.5%

Thu, 23 May 2013 14:17:59 -0400

Investors eyeing a purchase of Dendreon Corp (DNDN) shares, but tentative about paying the going market price of $3.92/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $2 strike, which has a bid at the time of this writing of 53 cents.

Commit To Buy Dendreon At $2, Earn 26.5%

Thu, 23 May 2013 14:17:59 -0400

Neuralstem Phase I Results Encourage Market, Stimulates Buying

Tue, 21 May 2013 09:07:39 -0400

Although it seems that investors have lost their appetite for many stem cell investments at this stage of the broader rally in the stock market, there are exceptions worth pointing out. Neuralstem (NASDAQ: CUR), for instance, has been in a strong uptrend since the company finally on April 17th that the company received approval from the [...]

Amarin Corporation plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX), and Dendreon Corp. (NASDAQ:DNDN) Added to Growing Stock Report's NASDAQ Decliners Watch List

Tue, 21 May 2013 08:38:16 -0400

New York, NY -- (SBWIRE) -- 05/21/2013 -- Growing Stock Report expands its NASDAQ Decliners Weekly Watch List adding Amarin Corporation plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX), and Dendreon Corp. (NASDAQ:DNDN).

Supernus Shorts See Losses, Dendreon Shorts Extend Gains

Mon, 20 May 2013 14:21:03 -0400

Two companies with extremely high short interest as of April 30th – Dendreon Corporation (NASDAQ: DNDN) and Supernus Pharmaceuticals (NASDAQ: SUPN) at 35.4% and 36% of shares short as percentage of float (respectively) saw radically different outcomes throughout the last three weeks. Dendreon is down about 16% since the start of the month after a disastrous [...]

NASDAQ Decliners Watch List: Amarin Corporation Plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX), and Dendreon Corp. (NASDAQ:DNDN) Added to Equity Profile Report's NASDAQ Decliners Watch List.

Mon, 20 May 2013 12:24:30 -0400

Wilmington, DE -- (SBWIRE) -- 05/20/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Amarin Corporation plc (NASDAQ:AMRN), Theravance Inc. (NASDAQ:THRX), and Dendreon Corp. (NASDAQ:DNDN).

The Straight Truth, Investing in JNJ, MGM, DNDN and AGNC

Wed, 15 May 2013 12:00:00 -0400

Stocks to Watch: Galena Biopharma Inc, Zagg Inc (NASDAQ:ZAGG), ARMOUR Residential REIT, Dendreon Corporation

Tue, 14 May 2013 09:38:35 -0400

Austin, TX -- (SBWIRE) -- 05/14/2013 -- Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-

Three of WellPoint's directors resign for personal reasons

Mon, 13 May 2013 19:58:02 -0400

May 13 (Reuters) - Health insurer WellPoint Inc said three of its directors resigned, effective immediately, citing personal reasons.

Stocks Closing Lower: AFFY, CLWR, DNDN, WG

Mon, 13 May 2013 11:30:00 -0400

New York, NY -- (SBWIRE) -- 05/13/2013 -- Affymax, Inc. (NASDAQ:AFFY) dropped 24.86% after trading 19.62 million shares. The beta of the stock is 1.00. With a book value per share of about 0.22 the price to book value ratio of the Affymax is close to 8.26 which is quite decent. The investors can get a clue about the stock’s performance from the investors holding in the company’s share which is close to 0.54% as of May 10, at the same time the institutional investors are holding about 83.81% in the company’s stock. The net profit margin over the trailing twelve months of the company is close to -98.98%. The analysts’ are expecting a price of $4.75 for the stock, thus we can expect the stock to rise further expect.

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert

Mon, 13 May 2013 08:00:40 -0400

Highlights on Block Activity and Options Trading for Dendreon

Mon, 13 May 2013 03:00:00 -0400

NEW YORK (AVAFIN) -- Financial institutions traded 42 block trades on shares of Dendreon. ...

Short Interest in Vertex Rises, in Celgene Falls

Sat, 11 May 2013 10:45:31 -0400

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.

The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ:

3 Stocks with Losing News (AFFY, DNDN, CFN)

Fri, 10 May 2013 14:12:38 -0400

New York, NY -- (SBWIRE) -- 05/10/2013 -- Affymax, Inc. (NASDAQ:AFFY) a biopharmaceutical company that engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses is currently down -23.48%. In its Form 10-Q filed with the SEC, Affymax said it has experienced significant operating losses since inception. The recall of Omontys has severely harmed its business, financial condition, and prospects as a going concern and even with the transition of responsibilities effectuated by the Takeda amendment and the reductions in force, these planned cost reductions may not be sufficient to continue as a going concern. The company continues to take steps to reduce its outstanding obligations to third parties, and are dependent on those efforts to continue operations even in the near term, which may not be successful. The recall has also limited the company's access to funds. The company may be unable to continue our operations or to succeed in the existing and potential future litigation, particularly with the reductions in force and in view of its limited resources and funds. The company may explore various strategic alternatives, including a sale of the company or its assets or a corporate merger. The company is considering all possible alternatives, including further restructuring activities, wind-down of operations or bankruptcy proceedings. As of March 31, the company had an accumulated deficit of $570.4M.

Closing Bell for Friday on Wall Street: Markets Open Mixed, Close Higher

Fri, 10 May 2013 12:07:00 -0400

DailyFinance.com: U.S. equity markets opened mixed this morning and failed to find a direction driver throughout the trading day. In Europe, Germany reported a stronger-than-expected trade surplus, while the U.K.'s trade deficit was slightly larger than expected. ... Read more

Notable Analyst Rating Changes 05/10: (FST) (EIX) (BSX) Upgraded; (MDR) (DNDN) (LTD) Downgraded

Fri, 10 May 2013 10:47:52 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8326447 for the full story.

UPDATE: Bank of America Lowers PT on Dendreon Following 1Q13 Miss, Increased Risks

Fri, 10 May 2013 10:17:08 -0400

In a report published Friday, Bank of America analyst Rachel McMinn reiterated an Underperform rating on Dendreon Corporation (NASDAQ: DNDN), and lowered the price target from $5.00 to $1.00.

In the report, McMinn noted, “DNDN announced 1Q13 Provenge sales of $67.6M, down 18% yr/yr and q/q on a pro

Stocks in Focus (The Goldfield Corporation, Golden Star Resources Ltd, Dendreon Corporation, ORBCOMM Inc)

Fri, 10 May 2013 10:16:31 -0400

Austin, TX -- (SBWIRE) -- 05/10/2013 -- Jackpotpennystocks.com, an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:-

Analyst Downgrades: Dendreon Corporation, McDermott International, and Universal Display Corporation

Fri, 10 May 2013 09:28:00 -0400

Analysts are weighing in today on biotech issue Dendreon Corporation (NASDAQ:DNDN), construction firm McDermott International (NYSE:MDR), and OLED specialist Universal Display Corporation (NASDAQ:PANL)...(Read More)

Free Research Reports on BSX, DNDN, GMCR and PPO Issued by the Paragon Report

Fri, 10 May 2013 08:20:00 -0400

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

Dendreon (DNDN) Q1/13 Results, Pricing the therapy is still the “electronic” collar on this dog’s neck – SELL

Fri, 10 May 2013 07:57:25 -0400

Net loss of $72 million, or $0.48 per share Net loss was $72 million or $0.48 per share, compared to $103.9 million, or $0.70 per share for Q1/2012. The decrease in net loss for the 2013 is primarily due to decreased costs associated with SG&A expenses. Net revenue from DNDN’s Provenge sales [...]

Citi Downgrades Dendreon (DNDN) to Sell

Fri, 10 May 2013 07:13:14 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8325611 for the full story.

4 Top Losers Should Watch Today (DNDN, RAX, MDR, ATVI)

Thu, 09 May 2013 15:03:05 -0400

New York, NY -- (SBWIRE) -- 05/09/2013 -- Dendreon Corporation (NASDAQ:DNDN) started today’s trading session at 4.38 and is now trading down 10.21%. The stock has a range of 3.95 and 4.40 with a volume of 12.03 million. DNDN has shown slight upticks in trading since the start of May 2013 but is still far off from the highs recorded in February. The stock is down 54.60% on its 52-week high of 9.34 but up 3.69% on its 52-week low of 3.69. Analysts have set a target price of 6.17 and the stock has a RSI of 34.17, suggesting of course, that DNDN is creeping close to being oversold.

Decreasing Stocks : Dendreon Corporation (NASDAQ:DNDN) , Goldfield Corp (NYSEMKT:GV)

Thu, 09 May 2013 15:00:00 -0400

New York, NY -- (SBWIRE) -- 05/09/2013 -- Dendreon Corporation (NASDAQ:DNDN) is a medical organization whose objective is to focus on cancer and convert lifestyles through the development, development, commercialization and production of novel therapeutics. The Company is applicable its skills in antigen recognition, technological innovation and cell handling to generate effective mobile immunotherapy (ACI) product applicants designed to activate an defense reaction in a variety of growth types.

Healthcare Stock Watch List: Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Dendreon Corp. (NASDAQ:DNDN), and Pfizer Inc. (NYSE:PFE) Added to Growing Stock Report's Healthcare Stock Watch List.

Thu, 09 May 2013 14:31:44 -0400

New York, NY -- (SBWIRE) -- 05/09/2013 -- Growing Stock Report expands its Healthcare Stock Weekly Watch List adding Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Dendreon Corp. (NASDAQ:DNDN), and Pfizer Inc. (NYSE:PFE).

Roth Capital Downgrades Dendreon (DNDN) to Sell

Thu, 09 May 2013 14:08:16 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8322709 for the full story.

UPDATE: Stifel Nicolaus Downgrades Dendreon (DNDN) to Sell

Thu, 09 May 2013 13:58:40 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8322585 for the full story.

Mid-Day Market Update: Precision Castparts Rises as Rackspace Plummets

Thu, 09 May 2013 13:06:39 -0400

Midway through trading Thursday, the Dow traded down 0.01 percent to 15,104.07 while the NASDAQ rose 0.05 percent to 3,414.18. The S&P also fell, decreasing 0.19 percent to 1,629.25.

Top Headline Tesla (NASDAQ: TSLA) reported earnings after the close yesterday, crushing estimates on both the top and bottom lines. Following

Mid-Morning Market Update: Tesla Soars on Earnings as LivePerson Gets Crushed

Thu, 09 May 2013 11:35:32 -0400

Following the market opening Thursday, the Dow traded down 0.09 percent to 15,092.07 while the NASDAQ fell 0.07 percent to 3,411.18. The S&P also fell, decreasing 0.23 percent to 1,628.25.

Top Headline Tesla (NASDAQ: TSLA) reported earnings after the close yesterday, crushing estimates on both the top and bottom lines.

Markets Retreat After Yesterday's Record Close

Thu, 09 May 2013 10:42:53 -0400

Jobless claims unexpectedly dropped to a five year low but the markets opened lower with the Dow losing 25 points to 15,079 after a record close yesterday. Nasdaq slipped 6 points to 3407.

UPDATE 2-Dendreon's cancer vaccine sales drop as competition heats up

Thu, 09 May 2013 10:40:06 -0400

* Co says competition, lack of patient access caused sales decline

Dendreon Shocks Market With PROVENGE Sales Decline In Q1 2013

Thu, 09 May 2013 10:19:22 -0400

Today Dendreon (NASDAQ: DNDN) shocked the market after reporting an extremely disappointing $67.6 M in PROVENGE (sipuleucel-T) sales for Q1 2013, representing a 17.56% decline relative to $82 M in revenue reported in Q1 2012. The net loss for the quarter did also decline to $72 million relative to a net loss of $103.9 M [...]

Dendreon Corp (DNDN) Reports In-Line Q1 Loss of 48c/Share

Thu, 09 May 2013 08:31:59 -0400

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8321026 for the full story.

Dendreon Announces First Quarter 2013 Results

Thu, 09 May 2013 08:30:00 -0400